Albany Molecular Research, Inc. (AMRI)
The Company is a global chemistry-based drug discovery and development company focused on identifying and developing novel biologically active small molecules with applications in the drug market.
Recs
EPS 08: .62 p/e 13.1
EPS 09: .05 p/e 162.8
EPS 10: .13 p/e 62.62
Fundamentally speaking, this is a sell
Recs
Profitable pharmacy research and development company with good valuation ratios and low debt. Also, I feel the chart has already reached the bottom.
Recs
L/R D/E ratio's look good.
Recs
BUYING AT 5 PER SHARE, stock is valued in my fair value estimates at 5.40 a share i expect movement at this price in late summer.
good company worth 5 or more a share.
Recs
On a strictly technical basis, my magic charts say this will outperform the S&P
Recs
total risky pick here. But I live close to albany molecular, and they are a big deal in town. granted it's albany ny though. I have seen them working on stuff, their head honchos are decent people and their workers are all high quality.
Recs
Albany Molecular Research is another case of the slow and steady turtle executing with a solid management team to deliver results. The past four quarters have shown rather large earnings beats and at 31 times earnings and with $3.14 per share in cash I think they can solidly deliver 15% stock price appreciation per annum. The price to book valuation is in-line if not just below the sector average and the long-term technicals show an ascending triangle that wants to break hgiher above $18. All signs pointing higher.
Nero
Sagetrade
Recs
Recs
Growing by pharmaceutical development and licensing or partnership with large pharma corps.
Recs
sc score 10, good earning forecast
Recs
Lagging CRO sector, plus participation in near term drug discovery candidates
Recs
a VALUE PROPOSITION
Recs
Strong company, recent run up on no news suggest good news coming.

RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 1 - 13 of 13